Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

Objectives Pembrolizumab is a programmed death receptor-1 masking antibody approved
for metastatic non–small cell lung cancer. This Phase 2 study (NCT02818920) of …

Tumor microenvironment (TME) plays a crucial role in the initiation and progression of lung
adenocarcinoma (LUAD); however, there is still a challenge in understanding the dynamic …

Simple Summary Neoadjuvant immunotherapy is a novel approach for lung cancer patients
in stages where curative intent treatment is possible. The rationale is a based on the idea …

Abstract Background and Objectives The role of salvage thoracic surgery in managing
advanced‐stage lung cancer following treatment with immune checkpoint inhibitors is …

One of the major hurdles for the advancement of cancer immunotherapy is lack of robust,
accessible experimental models. We aimed to produce an ex-vivo organ culture (EVOC) …

Molecularly targeted drugs are flourishing in the clinical treatment of non-small cell lung
cancer (NSCLC). However, the treatment of a single drug (such as Gefitinib (Geb)) had …

Background Lung cancer remains the foremost reason of cancer‐related mortality, with
invasion and metastasis profoundly influencing patient prognosis. N‐acetyltransferase 10 …

It has been recognized that Citrus reticulata and Pinellia ternata have a good therapeutic
effect on NSCLC. However, the potential mechanism of C. reticulata and P. ternata in the …

Simple Summary In this short communication, we present three cases of patients with
symptomatic, synchronous brain metastases of otherwise locally limited non-small cell lung …